Mount Sinai researchers have identified a crucial mechanism linking decreased immune cells to Crohn's disease development. The study reveals that gamma delta IELs, important white blood cells in the GI tract, diminish weeks before disease symptoms appear. This groundbreaking research establishes a clear timeline of immune system dysfunction in IBD development. The findings could lead to new treatment approaches and better methods for predicting disease progression in patients.
March 24, 2025
Researchers find mechanisms that may lead to inflammatory bowel disease
"Previous studies revealed a decrease in gamma
delta IELs in those with active IBD. However, it was unknown whether the loss
was a cause or consequence of disease" - Karen Edelblum, Mount Sinai
A team of scientists has discovered mechanisms of
abnormal immune cell function that may lead to Crohn's disease, an inflammatory
bowel disease (IBD).
Key Points: Gamma delta IELs decrease weeks before
clinical evidence of Crohn's disease appears
Crohn's disease causes chronic inflammation of the
gastrointestinal (GI) tract, and symptoms can include abdominal pain,
diarrhoea, weight loss, anaemia, and fatigue.
White blood cells in the GI tract known as
intraepithelial lymphocytes express the gamma delta T cell receptor (gamma
delta IELs), which prevent infection and provide surveillance for the
intestinal barrier. These gamma delta IELs are often reduced in patients with
active Crohn's disease.
A research team led by Mount Sinai said their study
is the first to show that gamma delta IELs are critical to maintain a balance
between pro-inflammatory and regulatory immune responses, and these cells are
impaired during the onset and progression of long-term inflammation in the
lower small intestine.
"Previous studies assessing patient biopsies
revealed a decrease in gamma delta IELs in those with active IBD. However, it
was unknown whether the loss of these cells was a cause or consequence of disease,"
said Karen Edelblum, Associate Professor of Pathology, Molecular and Cell-Based
Medicine at the Icahn School of Medicine at Mount Sinai.
The findings, published in Science Immunology, now
show that gamma delta IELs are substantially decreased weeks before clinical or
histological evidence of disease in a mouse model of Crohn's disease-like
ileitis.
Furthermore, "we were able to generate a
timeline of events leading to the dysregulation of gamma delta IELs that
mirrored findings from prior studies in patients with IBD," Edelblum said.
The researchers said loss of gamma delta IELs could
be used as a predictive biomarker for disease relapse or patient responsiveness
to treatment.
Additionally, development of future therapies that
boost the function of gamma delta IELs may provide a new way to maintain
remission in IBD patients or prevent disease development in susceptible
individuals.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment